18 October 2017
News and Views
Links and Services
A study in the most recent Clinical Gastroenterology & Hepatology investigates long-term outcome of patients with Crohn’s disease who discontinued infliximab therapy upon clinical remission.
There are limited data on the effects of discontinuing infliximab therapy for Crohn’s disease (CD
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors